Keros Therapeutics (KROS) Non Operating Interest Expenses (2019 - 2022)

Keros Therapeutics (KROS) has reported Non Operating Interest Expenses for 4 consecutive years, with $1000.0 the latest figure, recorded in Q1 2022.

• For the quarter ending Q1 2022, Non Operating Interest Expenses changed 0.0% year-over-year to $1000.0; the trailing twelve-month figure through Dec 2022 stood at $1000.0 (down 75.0% YoY), and the FY2022 full-year result was $1000.0, down 75.0% from the prior year.
• Non Operating Interest Expenses held at $1000.0 in Q1 2022 per KROS's latest filing, from $1000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $3000.0 in Q3 2019 and bottomed at $1000.0 in Q2 2020.
• Historically, Non Operating Interest Expenses has averaged $1500.0 across 4 years, with a median of $1000.0 in 2020.
• The widest YoY moves for Non Operating Interest Expenses: up 0.0% in 2020, down 50.0% in 2020.
• Over 4 years, Non Operating Interest Expenses stood at $3000.0 in 2019, then plunged by 66.67% to $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $1000.0, $1000.0, and $1000.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.